Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 3-4/2012

01-12-2012 | NON-THEMATIC REVIEW

Role of the EpCAM (CD326) in prostate cancer metastasis and progression

Authors: Jie Ni, Paul J. Cozzi, Wei Duan, Sarah Shigdar, Peter H. Graham, Kearsley H. John, Yong Li

Published in: Cancer and Metastasis Reviews | Issue 3-4/2012

Login to get access

Abstract

Despite significant advances in surgery, radiotherapy and chemotherapy to treat prostate cancer (CaP), many patients die of secondary disease (metastases). Current therapeutic approaches are limited, and there is no cure for metastatic castration-resistant prostate cancer (CRPC). Epithelial cell adhesion molecule (EpCAM, also known as CD326) is a transmembrane glycoprotein that is highly expressed in rapidly proliferating carcinomas and plays an important role in the prevention of cell–cell adhesion, cell signalling, migration, proliferation and differentiation. Stably and highly expressed EpCAM has been found in primary CaP tissues, effusions and CaP metastases, making it an ideal candidate of tumour-associated antigen to detect metastasis of CaP cells in the circulation as well as a promising therapeutic target to control metastatic CRPC disease. In this review, we discuss the implications of the newly identified roles of EpCAM in terms of its diagnostic and metastatic relevance to CaP. We also summarize EpCAM expression in human CaP and EpCAM-mediated signalling pathways in cancer metastasis. Finally, emerging and innovative approaches to the management of the disease and expanding potential therapeutic applications of EpCAM for targeted strategies in future CaP therapy will be explored.
Literature
1.
Beltran, H., Beer, T. M., Carducci, M. A., de Bono, J., Gleave, M., Hussain, M., et al. (2011). New therapies for castration-resistant prostate cancer: efficacy and safety. European Urology, 60, 279–290.PubMed
2.
Logothetis, C. J. (2002). Docetaxel in the integrated management of prostate cancer. Current applications and future promise. Oncology (Williston Park, N.Y.), 16(6 Suppl 6), 63–72.
3.
Petrylak, D. P., Tangen, C. M., Hussain, M. H., Lara, P. N., Jr., Jones, J. A., Taplin, M. E., et al. (2004). Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. The New England Journal of Medicine, 351(15), 1513–1520.PubMed
4.
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., et al. (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. The New England Journal of Medicine, 351, 1502–1512.PubMed
5.
Calabro, F., & Sternberg, C. N. (2007). Current indications for chemotherapy in prostate cancer patients. European Urology, 51, 17–26.PubMed
6.
Petrylak, D. P. (2005). Future directions in the treatment of androgen-independent prostate cancer. Urology, 65(6 Suppl), 8–12.PubMed
7.
Higano, C. S., & Crawford, E. D. (2011). New and emerging agents for the treatment of castration-resistant prostate cancer. Urologic Oncology, 29(6 Suppl), S1–S8.PubMed
8.
Caffo, O., Pappagallo, G., Brugnara, S., Caldara, A., di Pasquale, M. C., Ferro, A., et al. (2012). Multiple rechallenges for castration-resistant prostate cancer patients responding to first-line docetaxel: assessment of clinical outcomes and predictive factors. Urology, 79, 644–649.PubMed
9.
Hao, J. L., Cozzi, P. J., Khatri, A., Power, C. A., & Li, Y. (2010). CD147/EMMPRIN and CD44 are potential therapeutic target for metastatic prostate cancer. Current Cancer Drug Targets, 10, 287–306.PubMed
10.
Li, Y., Cozzi, P. J., & Russell, P. J. (2010). Promising tumor-associated antigens for future prostate cancer therapy. Medicinal Research Reviews, 30, 67–101.PubMed
11.
Li, Y., & Cozzi, P. J. (2010). Angiogenesis as a strategic target for prostate cancer therapy. Medicinal Research Reviews, 30, 23–66.PubMed
12.
Mukherji, D., Pezaro, C. J., & De-Bono, J. S. (2012). MDV3100 for the treatment of prostate cancer. Expert Opinion on Investigational Drugs, 21, 227–233.PubMed
13.
Villanueva, C., Bazan, F., Kim, S., Demarchi, M., Chaigneau, L., Thiery-Vuillemin, A., et al. (2011). Cabazitaxel: a novel microtubule inhibitor. Drugs, 71, 1251–1258.PubMed
14.
Bellmunt, J., Attard, G., Bahl, A., Huland, H., Klotz, L., Kuban, D., et al. (2012). Advances in the management of high-risk localised and metastatic prostate cancer. British Journal of Urology International, 109(Suppl 2), 8–13.
15.
Baeuerle, P. A., & Gires, O. (2007). EpCAM (CD326) finding its role in cancer. British Journal of Cancer, 96, 417–423.PubMed
16.
Patriarca, C., Macchi, R. M., Marschner, A. K., & Mellstedt, H. (2012). Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. Cancer Treatment Reviews, 38, 68–75.PubMed
17.
Went, P., Vasei, M., Bubendorf, L., Terracciano, L., Tornillo, L., Riede, U., et al. (2006). Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. British Journal of Cancer, 94, 128–135.PubMed
18.
Armstrong, A. J., Marengo, M. S., Oltean, S., Kemeny, G., Bitting, R. L., Turnbull, J. D., et al. (2011). Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Molecular Cancer Research, 9, 997–1007.PubMed
19.
Trzpis, M., McLaughlin, P. M., de Leij, L. M., & Harmsen, M. C. (2007). Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. The American Journal of Pathology, 171, 386–395.PubMed
20.
van der Gun, B. T., Melchers, L. J., Ruiters, M. H., de Leij, L. F., McLaughlin, P. M., & Rots, M. G. (2010). EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis, 31, 1913–1921.PubMed
21.
Seligson, D. B., Pantuck, A. J., Liu, X., Huang, Y., Horvath, S., Bui, M. H., et al. (2004). Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma. Clinical Cancer Research, 10, 2659–2669.PubMed
22.
Songun, I., Litvinov, S. V., van de Velde, C. J., Pals, S. T., Hermans, J., & van Krieken, J. H. (2005). Loss of Ep-CAM (CO17-1A) expression predicts survival in patients with gastric cancer. British Journal of Cancer, 92, 1767–1772.PubMed
23.
Ensinger, C., Kremser, R., Prommegger, R., Spizzo, G., & Schmid, K. W. (2006). EpCAM overexpression in thyroid carcinomas: a histopathological study of 121 cases. Journal of Immunotherapy, 29, 569–573.PubMed
24.
Kimura, H., Kato, H., Faried, A., Sohda, M., Nakajima, M., Fukai, Y., et al. (2007). Prognostic significance of EpCAM expression in human esophageal cancer. International Journal of Oncology, 30, 171–179.PubMed
25.
Hwang, E. Y., Yu, C. H., Cheng, S. J., Chang, J. Y., Chen, H. M., & Chiang, C. P. (2009). Decreased expression of Ep-CAM protein is significantly associated with the progression and prognosis of oral squamous cell carcinomas in Taiwan. Journal of Oral Pathology & Medicine, 38, 87–93.
26.
Spizzo, G., Went, P., Dirnhofer, S., Obrist, P., Simon, R., Spichtin, H., et al. (2004). High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Research and Treatment, 86, 207–213.PubMed
27.
Varga, M., Obrist, P., Schneeberger, S., Muhlmann, G., Felgel-Farnholz, C., Fong, D., et al. (2004). Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival. Clinical Cancer Research, 10, 3131–3136.PubMed
28.
Brunner, A., Prelog, M., Verdorfer, I., Tzankov, A., Mikuz, G., & Ensinger, C. (2008). EpCAM is predominantly expressed in high grade and advanced stage urothelial carcinoma of the bladder. Journal of Clinical Pathology, 61, 307–310.PubMed
29.
Fong, D., Steurer, M., Obrist, P., Barbieri, V., Margreiter, R., Amberger, A., et al. (2008). Ep-CAM expression in pancreatic and ampullary carcinomas: frequency and prognostic relevance. Journal of Clinical Pathology, 61, 31–35.PubMed
30.
Nubel, T., Preobraschenski, J., Tuncay, H., Weiss, T., Kuhn, S., Ladwein, M., et al. (2009). Claudin-7 regulates EpCAM-mediated functions in tumor progression. Molecular Cancer Research, 7, 285–299.PubMed
31.
Visvader, J. E., & Lindeman, G. J. (2008). Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nature Reviews. Cancer, 8, 755–768.PubMed
32.
Osta, W. A., Chen, Y., Mikhitarian, K., Mitas, M., Salem, M., Hannun, Y. A., et al. (2004). EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Research, 64, 5818–5824.PubMed
33.
Maetzel, D., Denzel, S., Mack, B., Canis, M., Went, P., Benk, M., et al. (2009). Nuclear signalling by tumour-associated antigen EpCAM. Nature Cell Biology, 11, 162–171.PubMed
34.
Munz, M., Baeuerle, P. A., & Gires, O. (2009). The emerging role of EpCAM in cancer and stem cell signaling. Cancer Research, 69, 5627–5629.PubMed
35.
Maaser, K., & Borlak, J. (2008). A genome-wide expression analysis identifies a network of EpCAM-induced cell cycle regulators. British Journal of Cancer, 99, 1635–1643.PubMed
36.
Gonzalez, B., Denzel, S., Mack, B., Conrad, M., & Gires, O. (2009). EpCAM is involved in maintenance of the murine embryonic stem cell phenotype. Stem Cells, 27, 1782–1791.PubMed
37.
Benko, G., Spajic, B., Kruslin, B., Tomas, D. (2012). Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer. Urologic Oncology (in press).
38.
Tewes, M., Aktas, B., Welt, A., Mueller, S., Hauch, S., Kimmig, R., et al. (2009). Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. Breast Cancer Research and Treatment, 115, 581–590.PubMed
39.
Paterlini-Brechot, P., & Benali, N. L. (2007). Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Letters, 253, 180–204.PubMed
40.
Mostert, B., Sleijfer, S., Foekens, J. A., & Gratama, J. W. (2009). Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer. Cancer Treatment Reviews, 35, 463–474.PubMed
41.
Kaiser, J. (2010). Medicine. Cancer's circulation problem. Science, 327, 1072–1074.PubMed
42.
Miller, M. C., Doyle, G. V., & Terstappen, L. W. (2010). Significance of circulating tumor cells detected by the cell search system in patients with metastatic breast colorectal and prostate cancer. Journal of Oncology, 2010, 617421.PubMed
43.
Morgan, T. M., Lange, P. H., & Vessella, R. L. (2007). Detection and characterization of circulating and disseminated prostate cancer cells. Frontiers in Bioscience, 12, 3000–3009.PubMed
44.
Nagrath, S., Sequist, L. V., Maheswaran, S., Bell, D. W., Irimia, D., Ulkus, L., et al. (2007). Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature, 450, 1235–1239.PubMed
45.
Stott, S. L., Hsu, C. H., Tsukrov, D. I., Yu, M., Miyamoto, D. T., Waltman, B. A., et al. (2010). Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proceedings of the National Academy of Sciences of the United States of America, 107, 18392–18397.PubMed
46.
Smerage, J. B., & Hayes, D. F. (2006). The measurement and therapeutic implications of circulating tumour cells in breast cancer. British Journal of Cancer, 94, 8–12.PubMed
47.
Moreno, J. G., Miller, M. C., Gross, S., Allard, W. J., Gomella, L. G., & Terstappen, L. W. (2005). Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology, 65, 713–718.PubMed
48.
Danila, D. C., Heller, G., Gignac, G. A., Gonzalez-Espinoza, R., Anand, A., Tanaka, E., et al. (2007). Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clinical Cancer Research, 13, 7053–7058.PubMed
49.
Garcia, J. A., Rosenberg, J. E., Weinberg, V., Scott, J., Frohlich, M., Park, J. W., et al. (2007). Evaluation and significance of circulating epithelial cells in patients with hormone-refractory prostate cancer. British Journal of Urology International, 99, 519–524.
50.
de Bono, J. S., Scher, H. I., Montgomery, R. B., Parker, C., Miller, M. C., Tissing, H., et al. (2008). Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clinical Cancer Research, 14, 6302–6309.PubMed
51.
Jost, M., Day, J. R., Slaughter, R., Koreckij, T. D., Gonzales, D., Kinnunen, M., et al. (2010). Molecular assays for the detection of prostate tumor derived nucleic acids in peripheral blood. Molecular Cancer, 9, 174.PubMed
52.
Kolostova, K., Pinterova, D., Hoffman, R. M., & Bobek, V. (2011). Circulating human prostate cancer cells from an orthotopic mouse model rapidly captured by immunomagnetic beads and imaged by GFP expression. Anticancer Research, 31, 1535–1539.PubMed
53.
Farace, F., Massard, C., Vimond, N., Drusch, F., Jacques, N., Billiot, F., et al. (2011). A direct comparison of Cell Search and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. British Journal of Cancer, 105, 847–853.PubMed
54.
Riethdorf, S., Fritsche, H., Muller, V., Rau, T., Schindlbeck, C., Rack, B., et al. (2007). Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the Cell Search system. Clinical Cancer Research, 13, 920–928.PubMed
55.
Wang, S., Owens, G. E., & Tseng, H. R. (2011). Nano “fly paper” technology for the capture of circulating tumor cells. Methods in Molecular Biology, 726, 141–150.PubMed
56.
Hoshino, K., Huang, Y. Y., Lane, N., Huebschman, M., Uhr, J. W., Frenkel, E. P., et al. (2011). Microchip-based immunomagnetic detection of circulating tumor cells. Lab on a Chip, 11, 3449–3457.PubMed
57.
Zheng, X., Cheung, L. S., Schroeder, J. A., Jiang, L., & Zohar, Y. (2011). A high-performance microsystem for isolating circulating tumor cells. Lab on a Chip, 11, 3269–3276.PubMed
58.
Dharmasiri, U., Njoroge, S. K., Witek, M. A., Adebiyi, M. G., Kamande, J. W., Hupert, M. L., et al. (2011). High-throughput selection, enumeration, electrokinetic manipulation, and molecular profiling of low-abundance circulating tumor cells using a microfluidic system. Analytical Chemistry, 83, 2301–2309.PubMed
59.
Poczatek, R. B., Myers, R. B., Manne, U., Oelschlager, D. K., Weiss, H. L., Bostwick, D. G., et al. (1999). Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. The Journal of Urology, 162, 1462–1466.PubMed
60.
Went, P. T., Lugli, A., Meier, S., Bundi, M., Mirlacher, M., Sauter, G., et al. (2004). Frequent EpCam protein expression in human carcinomas. Human Pathology, 35, 122–128.PubMed
61.
Zellweger, T., Ninck, C., Bloch, M., Mirlacher, M., Koivisto, P. A., Helin, H. J., et al. (2005). Expression patterns of potential therapeutic targets in prostate cancer. International Journal of Cancer, 113, 619–628.
62.
Cunha, G. R., Ricke, W., Thomson, A., Marker, P. C., Risbridger, G., Hayward, S. W., et al. (2004). Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development. The Journal of Steroid Biochemistry and Molecular Biology, 92, 221–236.PubMed
63.
Ghosh, K., & Ingber, D. E. (2007). Micromechanical control of cell and tissue development: implications for tissue engineering. Advanced Drug Delivery Reviews, 59, 1306–1318.PubMed
64.
Chung, L. W. (2005). Better to give than receive: my exciting journey in science. Cancer Biology & Therapy, 4, 348–352.
65.
Mukherjee, S., Richardson, A. M., Rodriguez-Canales, J., Ylaya, K., Erickson, H. S., Player, A., et al. (2009). Identification of EpCAM as a molecular target of prostate cancer stroma. The American Journal of Pathology, 175, 2277–2287.PubMed
66.
Furusato, B., Tsunoda, T., Shaheduzzaman, S., Nau, M. E., Vahey, M., Petrovics, G., et al. (2010). Osteoblast-specific factor 2 expression in prostate cancer-associated stroma: identification through microarray technology. Urology, 75, 768–772.PubMed
67.
Sung, S. Y., & Chung, L. W. (2002). Prostate tumor–stroma interaction: molecular mechanisms and opportunities for therapeutic targeting. Differentiation, 70, 506–521.PubMed
68.
Richardson, A. M., Woodson, K., Wang, Y., Rodriguez-Canales, J., Erickson, H. S., Tangrea, M. A., et al. (2007). Global expression analysis of prostate cancer-associated stroma and epithelia. Diagnostic Molecular Pathology, 16, 189–197.PubMed
69.
Munz, M., Kieu, C., Mack, B., Schmitt, B., Zeidler, R., & Gires, O. (2004). The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene, 23, 5748–5758.PubMed
70.
Eferl, R., & Wagner, E. F. (2003). AP-1: a double-edged sword in tumorigenesis. Nature Reviews. Cancer, 3, 859–868.PubMed
71.
Sankpal, N. V., Mayfield, J. D., Willman, M. W., Fleming, T. P., & Gillanders, W. E. (2011). Activator protein 1 (AP-1) contributes to EpCAM-dependent breast cancer invasion. Breast Cancer Research, 13, R124.PubMed
72.
Gostner, J. M., Fong, D., Wrulich, O. A., Lehne, F., Zitt, M., Hermann, M., et al. (2011). Effects of EpCAM overexpression on human breast cancer cell lines. BMC Cancer, 11, 45.PubMed
73.
Carpenter, G., & Red Brewer, M. (2009). EpCAM: another surface-to-nucleus missile. Cancer Cell, 15, 165–166.PubMed
74.
Denzel, S., Maetzel, D., Mack, B., Eggert, C., Barr, G., & Gires, O. (2009). Initial activation of EpCAM cleavage via cell-to-cell contact. BMC Cancer, 9, 402.PubMed
75.
Naundorf, S., Preithner, S., Mayer, P., Lippold, S., Wolf, A., Hanakam, F., et al. (2002). In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment. International Journal of Cancer, 100, 101–110.
76.
Kurtz, J. E., & Dufour, P. (2010). Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside. Expert Opinion on Biological Therapy, 10, 951–958.PubMed
77.
Gires, O., & Bauerle, P. A. (2010). EpCAM as a target in cancer therapy. Journal of Clinical Oncology, 28(15), e239–240. author reply e241–e232.PubMed
78.
Bellati, F., Napoletano, C., Gasparri, M. L., Visconti, V., Zizzari, I. G., Ruscito, I., et al. (2011). Monoclonal antibodies in gynecological cancer: a critical point of view. Clinical & Developmental Immunology, 2011, 890758.
79.
Groth, A., Salnikov, A. V., Ottinger, S., Gladkich, J., Liu, L., Kallifatidis, G., et al. (2012). New gene-immunotherapy combining TRAIL-lymphocytes and EpCAMxCD3 bispecific antibody for tumor targeting. Clinical Cancer Research, 18, 1028–1038.PubMed
80.
Oberneder, R., Weckermann, D., Ebner, B., Quadt, C., Kirchinger, P., Raum, T., et al. (2006). A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients. European Journal of Cancer, 42, 2530–2538.PubMed
81.
Suzuki, K., Nakamura, K., Kato, K., Hamada, H., & Tsukamoto, T. (2007). Exploration of target molecules for prostate cancer gene therapy. The Prostate, 67, 1163–1173.PubMed
82.
Moldenhauer, G., Salnikov, A. V., Luttgau, S., Herr, I., Anderl, J., & Faulstich, H. (2012). Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma. Journal of the National Cancer Institute, 104, 622–634.PubMed
83.
Yamashita, T., Ji, J., Budhu, A., Forgues, M., Yang, W., Wang, H. Y., et al. (2009). EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology, 136, 1012–1024.PubMed
84.
Terris, B., Cavard, C., & Perret, C. (2010). EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma. Journal of Hepatology, 52, 280–281.PubMed
85.
Kawashima, R., Abei, M., Fukuda, K., Nakamura, K., Murata, T., Wakayama, M., et al. (2011). EpCAM- and EGFR-targeted selective gene therapy for biliary cancers using Z33-fiber-modified adenovirus. International Journal of Cancer, 129, 1244–1253.
86.
Marme, A., Strauss, G., Bastert, G., Grischke, E. M., & Moldenhauer, G. (2002). Intraperitoneal bispecific antibody (HEA125xOKT3) therapy inhibits malignant ascites production in advanced ovarian carcinoma. International Journal of Cancer, 101, 183–189.
87.
Salnikov, A. V., Groth, A., Apel, A., Kallifatidis, G., Beckermann, B. M., Khamidjanov, A., et al. (2009). Targeting of cancer stem cell marker EpCAM by bispecific antibody EpCAMxCD3 inhibits pancreatic carcinoma. Journal of Cellular and Molecular Medicine, 13, 4023–4033.PubMed
88.
Ammons, W. S., Bauer, R. J., Horwitz, A. H., Chen, Z. J., Bautista, E., Ruan, H. H., et al. (2003). In vitro and in vivo pharmacology and pharmacokinetics of a human engineered monoclonal antibody to epithelial cell adhesion molecule. Neoplasia, 5, 146–154.PubMed
89.
Goel, S., Bauer, R. J., Desai, K., Bulgaru, A., Iqbal, T., Strachan, B. K., et al. (2007). Pharmacokinetic and safety study of subcutaneously administered weekly ING-1, a human engineere monoclonal antibody targeting human EpCAM, in patients with advanced solid tumors. Annals of Oncology, 18, 1704–1707.PubMed
90.
Winkler, J., Martin-Killias, P., Pluckthun, A., & Zangemeister-Wittke, U. (2009). EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins. Molecular Cancer Therapeutics, 8, 2674–2683.PubMed
91.
Seimetz, D., Lindhofer, H., & Bokemeyer, C. (2010). Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. Cancer Treatment Reviews, 36, 458–467.PubMed
92.
Heiss, M. M., Strohlein, M. A., Jager, M., Kimmig, R., Burges, A., Schoberth, A., et al. (2005). Immunotherapy of malignant ascites with trifunctional antibodies. International Journal of Cancer, 117, 435–443.
93.
Burges, A., Wimberger, P., Kumper, C., Gorbounova, V., Sommer, H., Schmalfeldt, B., et al. (2007). Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study. Clinical Cancer Research, 13, 3899–3905.PubMed
94.
Jager, M., Schoberth, A., Ruf, P., Hess, J., Hennig, M., Schmalfeldt, B., et al. (2012). Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3). Cancer Research, 72, 24–32.PubMed
95.
Shigdar, S., Lin, J., Yu, Y., Pastuovic, M., Wei, M., & Duan, W. (2011). RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule. Cancer Science, 102, 991–998.PubMed
96.
Barbas, A. S., & White, R. R. (2009). The development and testing of aptamers for cancer. Current Opinion in Investigational Drugs, 10, 572–578.PubMed
97.
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003). Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 100, 3983–3988.PubMed
98.
Dalerba, P., Cho, R. W., & Clarke, M. F. (2007). Cancer stem cells: models and concepts. Annual Review of Medicine, 58, 267–284.PubMed
99.
O'Brien, C. A., Pollett, A., Gallinger, S., & Dick, J. E. (2007). A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature, 445, 106–110.PubMed
100.
Li, C., Heidt, D. G., Dalerba, P., Burant, C. F., Zhang, L., Adsay, V., et al. (2007). Identification of pancreatic cancer stem cells. Cancer Research, 67, 1030–1037.PubMed
101.
Lugli, A., Iezzi, G., Hostettler, I., Muraro, M. G., Mele, V., Tornillo, L., et al. (2010). Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. British Journal of Cancer, 103, 382–390.PubMed
102.
Han, M. E., Jeon, T. Y., Hwang, S. H., Lee, Y. S., Kim, H. J., Shim, H. E., et al. (2011). Cancer spheres from gastric cancer patients provide an ideal model system for cancer stem cell research. Cellular and Molecular Life Sciences, 68, 3589–3605.PubMed
103.
Meirelles, K., Benedict, L. A., Dombkowski, D., Pepin, D., Preffer, F. I., Teixeira, J., et al. (2012). Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance. Proceedings of the National Academy of Sciences of the United States of America, 109, 2358–2363.PubMed
104.
Coumans, F. A., Doggen, C. J., Attard, G., de Bono, J. S., & Terstappen, L. W. (2010). All circulating EpCAM+CK+CD45− objects predict overall survival in castration-resistant prostate cancer. Annals of Oncology, 21, 1851–1857.PubMed
105.
Aktas, B., Muller, V., Tewes, M., Zeitz, J., Kasimir-Bauer, S., Loehberg, C. R., et al. (2011). Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. Gynecologic Oncology, 122, 356–360.PubMed
Metadata
Title
Role of the EpCAM (CD326) in prostate cancer metastasis and progression
Authors
Jie Ni
Paul J. Cozzi
Wei Duan
Sarah Shigdar
Peter H. Graham
Kearsley H. John
Yong Li
Publication date
01-12-2012
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 3-4/2012
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-012-9389-1

Other articles of this Issue 3-4/2012

Cancer and Metastasis Reviews 3-4/2012 Go to the issue

NON-THEMATIC REVIEW

Cancer stem cells, microRNAs, and therapeutic strategies including natural products

OriginalPaper

Insights into the biology and prevention of tumor metastasis provided by the Nm23 metastasis suppressor gene

Non-Thematic Review

Pharmacological strategies to spare normal tissues from radiation damage: useless or overlooked therapeutics?

NON-THEMATIC REVIEW

Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation—diversity, ductility, and destiny

OriginalPaper

Raf kinase inhibitor protein (RKIP) in cancer

Announcement

Biographies
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits